Newsmeme!
Discover News you didn't know existed
Osteoclasts
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
Treatment Of Rare Type Of Bone Tumour: Promising Results With Denosumab
Published February 10, 2010, 3:45 am, Medical News Today
Denosumab is a targeted therapy to prevent bone loss. It stops progressive bone destruction and tumour spread in some patients with inoperable giant-cell tumour (GCT) of bone. An article published Online First in The Lancet Oncology reports this could change standard treatment practice. Breaking new ground, this work is the first to clearly show a promising systemic treatment option for this ...
Activist Investor Pushes Celera to Divest Merck Bone Drug Royalties
Published February 9, 2010, 6:05 pm, BioWorld
The Biotechnology Value Fund (BVF), a historically activist investor group, revealed in a 13-D filing Tuesday the reason for its recent interest in diagnostics firm Celera Corp.: BVF wants Celera to spin out its royalty interest in Merck & Co. Inc.'s Phase III osteoporosis drug, odanacatib.
Denosumab Demonstrated Superiority Over Zometa(R) In Pivotal Phase 3 Head-to-Head Trial In Prostate Cancer Patients ...
Published February 9, 2010, 4:19 am, Medical News Today
Amgen (Nasdaq: AMGN) announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa® (zoledronic acid) in the treatment of bone metastases in 1,901 men with advanced prostate cancer met its primary and secondary endpoints. Denosumab demonstrated superiority over Zometa for both delaying the time to the first on-study skeletal related event (SRE) (fracture, radiation to ...
Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients ...
Published February 8, 2010, 7:08 pm, redOrbit
THOUSAND OAKS, Calif., Feb.
Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients ...
Published February 8, 2010, 3:20 pm, PR Newswire via Yahoo! Finance
Amgen today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa® in the treatment of bone metastases in 1,901 men with advanced prostate cancer met its primary and secondary endpoints.
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |